公开(公告)号：US20240174729A1

公开(公告)日：2024-05-30

申请号：US18482223

申请日：2023-10-06

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Aaron Michael Ring ,  Andrew Kruse ,  Aashish Manglik ,  Irving L. Weissman ,  Roy Louis Maute ,  Melissa N. McCracken ,  Sydney Gordon

IPC: C07K14/705 ,  A61K35/17 ,  A61K38/17 ,  A61K45/06 ,  A61K47/68 ,  A61K48/00 ,  A61K51/08 ,  A61K51/10 ,  C07K14/47 ,  C07K14/725 ,  A61K38/00

CPC classification number: C07K14/70503 ,  A61K35/17 ,  A61K38/1761 ,  A61K38/177 ,  A61K45/06 ,  A61K47/6849 ,  A61K48/00 ,  A61K51/08 ,  A61K51/088 ,  A61K51/10 ,  C07K14/4747 ,  C07K14/7051 ,  C07K14/70532 ,  A61K38/00 ,  C07K2319/30

Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.

公开(公告)号：US11905301B2

公开(公告)日：2024-02-20

申请号：US17393837

申请日：2021-08-04

Applicant: Clarity Pharmaceuticals Ltd.

Inventor： Paul Stephen Donnelly ,  Michelle Therese Ma ,  Denis Bernard Scanlon

IPC: A61K8/72 ,  C07D521/00 ,  A61K51/04 ,  A61K51/08 ,  A61K49/10 ,  A61K49/08 ,  A61K49/06 ,  A61K51/00 ,  A61K51/02 ,  A61K51/10

CPC classification number: C07D521/00 ,  A61K51/0482 ,  A61K51/082 ,  A61K51/088 ,  A61K49/06 ,  A61K49/08 ,  A61K49/10 ,  A61K49/101 ,  A61K51/00 ,  A61K51/02 ,  A61K51/04 ,  A61K51/08 ,  A61K51/10 ,  A61K51/106

Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

公开(公告)号：US20230272079A1

公开(公告)日：2023-08-31

申请号：US18167012

申请日：2023-02-09

Applicant: E.R. SQUIBB & SONS, L.L.C. ,  Ono Pharmaceutical Co., LTD.

Inventor： Alan J. KORMAN ,  Mohan SRINIVASAN ,  Changyu WANG ,  Mark J. SELBY ,  Bingliang CHEN ,  Josephine M. CARDARELLI ,  Haichun HUANG

IPC: C07K16/28 ,  A61P7/06 ,  A61K47/68 ,  C07K16/18 ,  A61K39/395 ,  C07K16/46 ,  A61K51/10 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61P7/06 ,  A61K47/6849 ,  C07K16/18 ,  A61K39/3955 ,  C07K16/468 ,  A61K51/10 ,  C07K16/28 ,  A61K39/39558 ,  A61K39/00 ,  C07K16/2803 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/52 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  Y02A50/30 ,  C07K2317/73 ,  A61K2039/507 ,  C07K2317/33 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.

公开(公告)号：US20190194319A1

公开(公告)日：2019-06-27

申请号：US16302995

申请日：2017-05-19

Applicant: ABBVIE STEMCENTRX LLC

Inventor： JEFFREY BERNSTEIN ,  LAURA SAUNDERS ,  SHEILA BHEDDAH ,  ENYING YOU ,  CASEY FRANKLIN ,  TIEN YIN YAU ,  GRAYSON KOCHI

IPC: C07K16/28 ,  A61K39/395 ,  A61K51/10 ,  A61K49/00 ,  C07K16/40 ,  G01N33/563 ,  C07K16/46

CPC classification number: C07K16/28 ,  A61K39/395 ,  A61K49/0058 ,  A61K51/10 ,  C07K16/18 ,  C07K16/30 ,  C07K16/40 ,  C07K16/46 ,  G01N33/563

Abstract: Compositions comprising Achaete-scute homolog 1 (ASCL1) antibodies, and methods comprising ASCL1 antibody compositions for detecting ASCL1 expression as a diagnostic biomarker, are provided.

公开(公告)号：US20180335436A1

公开(公告)日：2018-11-22

申请号：US15897609

申请日：2018-02-15

Applicant: University of Iowa Research Foundation

Inventor： Gregory S. Hageman ,  Robert F. Mullins

IPC: G01N33/68 ,  G01N33/564 ,  C12Q1/6883 ,  A61K51/10 ,  A61K47/46 ,  A61K38/00

CPC classification number: G01N33/6893 ,  A61K38/00 ,  A61K47/46 ,  A61K51/10 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/564 ,  G01N33/6896 ,  G01N2333/4716 ,  G01N2800/164

Abstract: The invention relates to methods for treating, preventing and diagnosing macular degeneration-related disorders.

公开(公告)号：US20170226230A1

公开(公告)日：2017-08-10

申请号：US15385735

申请日：2016-12-20

Applicant: True North Therapeutics, Inc.

Inventor： Peter Van Vlasselaer ,  Graham Parry ,  Nancy E. Stagliano ,  Sandip Panicker

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A01N1/021 ,  A61K49/00 ,  A61K49/16 ,  A61K51/10 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C12Y304/21042 ,  G01N33/6893 ,  G01N2800/52

Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

公开(公告)号：US09637741B2

公开(公告)日：2017-05-02

申请号：US14957102

申请日：2015-12-02

Applicant: National Yang-Ming University ,  The Board of Trustees of the Leland Stanford Junior University

Inventor： Tzu-Hao Cheng ,  Chia-Rung Liu ,  Tzu-Han Wang ,  Stanley N. Cohen

IPC: C12Q1/68 ,  C12N15/113 ,  A61K31/713 ,  G01N33/50 ,  C12N5/00 ,  A61K51/10

CPC classification number: C12N15/113 ,  A61K31/713 ,  A61K51/10 ,  A61K51/1075 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q1/6876 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5023

Abstract: This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease.

公开(公告)号：US09562087B2

公开(公告)日：2017-02-07

申请号：US14931725

申请日：2015-11-03

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Aaron Michael Ring ,  Andrew Kruse ,  Aashish Manglik ,  Irving L. Weissman ,  Roy Louis Maute ,  Melissa N. McCracken ,  Sydney Gordon

IPC: C07K14/705 ,  A61K38/00 ,  A61K51/08

CPC classification number: C07K14/70503 ,  A61K35/17 ,  A61K38/00 ,  A61K45/06 ,  A61K48/00 ,  A61K51/08 ,  A61K51/088 ,  A61K51/10 ,  C07K14/4747 ,  C07K14/7051 ,  C07K14/70532 ,  C07K2319/30

Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.

公开(公告)号：US09226935B2

公开(公告)日：2016-01-05

申请号：US13936696

申请日：2013-07-08

Applicant: Tzu-Hao Cheng ,  Chia-Rung Lu ,  Tzu-Han Wang ,  Stanley N. Cohen

Inventor： Tzu-Hao Cheng ,  Chia-Rung Lu ,  Tzu-Han Wang ,  Stanley N. Cohen

IPC: A61P25/00 ,  A61K31/713 ,  C12N15/113 ,  C12Q1/68 ,  A61K51/10

CPC classification number: C12N15/113 ,  A61K31/713 ,  A61K51/10 ,  A61K51/1075 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q1/6876 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5023

Abstract: This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease.

Abstract translation: 本发明提供了调节细胞中第一个基因表达的方法，其中第一个基因是含有多于36个CAG三核苷酸重复序列的基因，并编码形成聚谷氨酰胺介导的蛋白质聚集的蛋白质。 通过降低SPT4基因或SUPT4H基因的表达来实现第一个基因的抑制。 也可以通过抑制Spt4 / Spt5复合物或Supt4h / Supt5h复合物的形成来实现。 还提供了用于鉴定可用于调节CAG扩增的基因产物的表达和聚集或治疗诸如亨廷顿病的多聚谷氨酰胺病的药剂的方法。

公开(公告)号：US20150359913A1

公开(公告)日：2015-12-17

申请号：US14763380

申请日：2014-01-24

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  THE GENERAL HOSPITAL CORPORATION

Inventor： Thomas Reiner ,  Jason Stuart Lewis ,  Ralph Weissleder ,  Brian Zeglis

IPC: A61K51/10 ,  A61K51/04 ,  A61K49/04

CPC classification number: A61K51/10 ,  A61K47/6897 ,  A61K49/04 ,  A61K51/044 ,  A61K51/0453 ,  B82Y5/00 ,  C07K16/3046

Abstract: This invention is in the field of labeled peptide construction for medical treatment and analysis. The invention relates to synthetic labeled peptide compositions, methods of synthesis, and methods of use for the synthetic labeled peptide compositions for medical treatment, imaging, and research purposes.

Abstract translation: 本发明涉及用于医疗和分析的标记肽结构领域。 本发明涉及用于医疗，成像和研究目的的合成标记肽组合物，合成方法和合成标记肽组合物的使用方法。